Nano Interface Technology, Inc. to Present at Medtech Insight's 'Investment In Innovation' Conference
Nano Interface Technology, Inc. (NITI) founded in 1997 has developed nanotechnology-derived economical ultra-pure coatings for orthopedic and dental implants which FDA has been in quest for many years. The NIH Nanotech review panel validates NITI's proprietary technology by stating excellent quality of the product and its enormous clinical benefits. For the last 20 years, the lifespan of orthopedic and dental implants has been 10-12 years with revision rate of 17%. The ultra-pure coatings developed by the NITI will increase the lifespan of these implants from 12 years to 20 years or longer resulting in significantly reduced revision. It will also reduce the use of high strength painkillers. The reduction in the revision rate of hip and knee implants from 17% to 12% has the potential of saving $825M per year in the US alone. Since this material is currently used in coating of implants, therefore implants developed using this purer material will easily get FDA approval without any clinical studies. It will be widely accepted by the consumers because the cost of these implants will be significantly lower than the existing cost of such implants.
“Investment In Innovation (In3): A Preview of Early-Stage Medical Technology Companies”
NITI has completed the research and will market the products after in vivo studies in the next 3 years. NITI will provide coatings for orthopedic implants to manufacturers for higher growth in revenue and plans to license its technology to the existing players in the dental implants business. The leading dental implants companies have already contacted NITI for partnership. The worldwide market size of the orthopedic and dental implants is $15B per year with 15% growth rate. The growth rate of 15% will increase to 25% due to the longer life expectancy and several painkillers for arthritis are being pulled out from the market, resulting in $30B market by 2009. NITI foresees annual revenue of $133 Million by 2012 based on market shares of 1% in orthopedic and 10% in dental implants. NITI provides excellent opportunity for capturing 70% of $15B implants' market by providing superior coatings of biomaterials on the implants, similar to the success of Boston Scientific in $4B stents' market by providing better coatings of drugs on the stents. The Wall Street Reporter interviewed the founder of NITI on May 23, 2005 about business opportunity utilizing NITI's developed products. For general information, please visit www.nanointerfacetech.com. Certain statements included in this press release may constitute forward-looking statements.
Medtech Insight, a division of Windhover Information Inc., is the leading provider of business information and market intelligence for the medical technology marketplace. To register for the "Investment In Innovation" conference or for more information on Medtech Insight, please call Kristy Grimes at 480-985-9512, e-mail email@example.com, or visit www.medtechinsight.com.